Cover of: Endorphins and opiate antagonists in psychiatric research | Read Online
Share

Endorphins and opiate antagonists in psychiatric research clinical implications by

  • 747 Want to read
  • ·
  • 72 Currently reading

Published by Plenum Medical Book Co. in New York .
Written in English

Subjects:

  • Psychology, Pathological -- Physiological aspects.,
  • Endorphins.,
  • Narcotic antagonists.

Book details:

Edition Notes

Includes bibliographies and index.

Statementedited by Nandkumar S. Shah and Alexander G. Donald.
ContributionsShah, Nandkumar S., Donald, Alexander G., 1928-
Classifications
LC ClassificationsRC455.4.B5 E53 1982
The Physical Object
Paginationxxi, 488 p. :
Number of Pages488
ID Numbers
Open LibraryOL3491433M
ISBN 100306408783
LC Control Number82011237

Download Endorphins and opiate antagonists in psychiatric research

PDF EPUB FB2 MOBI RTF

Endorphins and Opiate Antagonists in Psychiatric Research Clinical Implications. Authors: Shah, Nandkumar S., Donald, Alexander G. Free PreviewBrand: Springer US.   Psychiatric Annals | Shah N.S. and Donald A.G. (editors) ENDORPHINS AND OPIATE ANTAGONISTS IN PSYCHIATRIC RESEARCH: CLINICAL IMPLICATIONS New York: Plenum Medical Book Company, , 4T8 pp., $39 Author: Wayne Creelman. Get this from a library! Endorphins and Opiate Antagonists in Psychiatric Research: Clinical Implications. [Nandkumar S Shah; Alexander G Donald] -- The discovery of new molecules that function in neuronal communication can be viewed as a progression of steps beginning with the identification of the molecular structure, moving to the. Current Status of Endorphins and Opiate Antagonists in Psychiatry: An Overview.- 1 The Opiate Receptor and its Endogenous Ligands: An Overview.- 2 The Endorphins and Analgesia: A Minireview.- 3 Central Nervous System Effects after Systemic Injection of Opiate Peptides.- 4 Possible Roles of Prostaglandins in Mediating Opioid Actions.- 5.

Opioid agonists and antagonists can modulate alcohol consumption and opioid antagonists are therefore used in pharmacotherapy of AUD. There are three different receptor types—mu-, delta- and kappa-opioid receptors—with different affinity for the three opioid peptides: beta-endorphin, enkephalin, and dynorphin. Despite concerns of addiction and misuse potential further research to study endorphin agonists for diverse psychiatric disorders seems warranted. Introduction. Endorphins and endorphin agonists play a crucial role in the neural modulation of mood, anxiety, pain and addiction [1,2]. Literature References: Generic name derived from the term "endogenous morphine" and applied to a group of neuropeptides that are endogenous ligands of the opiate receptors. They are found in brain, pituitary gland and peripheral tissues of all vertebrates; the effects of endorphins on cells resemble those of opiates such as morphine. that an opioid antagonist might alleviate some of these symptoms related to the increase in endorphin activity. This review will present our findings concerning the use of opiate antagonists in schizophrenia. NALTREXONE In an uncontrolled study using the oral opiate antago- nist naltrexone, Mielke & Gallant (24) evaluated five.

F. E. Bloom, J. Rossier, E. L. F. Battenberg, A. Bayon, E. French, S. J. Henriksen et al. Pages Immunohistochemical and biochemical studies of the enkephalins. Opioid agonists and antagonists can modulate alcohol consumption and opioid antagonists are therefore used in pharmacotherapy of AUD. There are three different receptor types—mu-, delta- and kappa-opioid receptors—with different affinity for the three opioid peptides: beta-endorphin, enkephalin, and dynorphin. The three systems also mediate. Research investigating central opioid functioning is therefore necessary if we are to understand their role in NSSI. While the CSF concentration of endogenous opioids (β-endorphin, met-enkephalin and dynorphin) in individuals with a history of self-injury has not been examined, lower levels of endogenous opioids have been implicated in the. The opioid theories in autism have been based on 1) symptom profiles seen in autism, 2) reported therapeutic effects of opiate antagonists and 3) reported abnormalities in opioid levels measured in individuals with autistic disorder, such as β-endorphin (BE).